PGEN
Price
$1.42
Change
-$0.01 (-0.70%)
Updated
Jun 27 closing price
Capitalization
419.16M
42 days until earnings call
VNDA
Price
$4.78
Change
-$0.04 (-0.83%)
Updated
Jun 27 closing price
Capitalization
282M
25 days until earnings call
Interact to see
Advertisement

PGEN vs VNDA

Header iconPGEN vs VNDA Comparison
Open Charts PGEN vs VNDABanner chart's image
Precigen
Price$1.42
Change-$0.01 (-0.70%)
Volume$5.16M
Capitalization419.16M
Vanda Pharmaceuticals
Price$4.78
Change-$0.04 (-0.83%)
Volume$716.33K
Capitalization282M
PGEN vs VNDA Comparison Chart in %
Loading...
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
PGEN vs. VNDA commentary
Jun 30, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is PGEN is a Buy and VNDA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Jun 30, 2025
Stock price -- (PGEN: $1.41 vs. VNDA: $4.78)
Brand notoriety: PGEN and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: PGEN: 315% vs. VNDA: 154%
Market capitalization -- PGEN: $419.16M vs. VNDA: $281.71M
PGEN [@Biotechnology] is valued at $419.16M. VNDA’s [@Biotechnology] market capitalization is $281.71M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.3B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

PGEN’s FA Score shows that 0 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • PGEN’s FA Score: 0 green, 5 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, VNDA is a better buy in the long-term than PGEN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

PGEN’s TA Score shows that 3 TA indicator(s) are bullish while VNDA’s TA Score has 6 bullish TA indicator(s).

  • PGEN’s TA Score: 3 bullish, 5 bearish.
  • VNDA’s TA Score: 6 bullish, 2 bearish.
According to our system of comparison, VNDA is a better buy in the short-term than PGEN.

Price Growth

PGEN (@Biotechnology) experienced а -2.76% price change this week, while VNDA (@Biotechnology) price change was +5.64% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.13%. For the same industry, the average monthly price growth was +31.22%, and the average quarterly price growth was +12.91%.

Reported Earning Dates

PGEN is expected to report earnings on Aug 11, 2025.

VNDA is expected to report earnings on Jul 24, 2025.

Industries' Descriptions

@Biotechnology (+4.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
PGEN($419M) has a higher market cap than VNDA($282M). PGEN YTD gains are higher at: 25.893 vs. VNDA (-0.209). VNDA has higher annual earnings (EBITDA): -64.56M vs. PGEN (-154.85M). VNDA has more cash in the bank: 341M vs. PGEN (80.2M). PGEN has less debt than VNDA: PGEN (5.42M) vs VNDA (11.7M). VNDA has higher revenues than PGEN: VNDA (201M) vs PGEN (4.2M).
PGENVNDAPGEN / VNDA
Capitalization419M282M149%
EBITDA-154.85M-64.56M240%
Gain YTD25.893-0.209-12,403%
P/E RatioN/A137.00-
Revenue4.2M201M2%
Total Cash80.2M341M24%
Total Debt5.42M11.7M46%
FUNDAMENTALS RATINGS
PGEN vs VNDA: Fundamental Ratings
PGEN
VNDA
OUTLOOK RATING
1..100
2612
VALUATION
overvalued / fair valued / undervalued
1..100
70
Overvalued
83
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10093
PRICE GROWTH RATING
1..100
4353
P/E GROWTH RATING
1..100
1002
SEASONALITY SCORE
1..100
3050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PGEN's Valuation (70) in the null industry is in the same range as VNDA (83) in the Biotechnology industry. This means that PGEN’s stock grew similarly to VNDA’s over the last 12 months.

PGEN's Profit vs Risk Rating (100) in the null industry is in the same range as VNDA (100) in the Biotechnology industry. This means that PGEN’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's SMR Rating (93) in the Biotechnology industry is in the same range as PGEN (100) in the null industry. This means that VNDA’s stock grew similarly to PGEN’s over the last 12 months.

PGEN's Price Growth Rating (43) in the null industry is in the same range as VNDA (53) in the Biotechnology industry. This means that PGEN’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's P/E Growth Rating (2) in the Biotechnology industry is significantly better than the same rating for PGEN (100) in the null industry. This means that VNDA’s stock grew significantly faster than PGEN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
PGENVNDA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
82%
Momentum
ODDS (%)
Bearish Trend 3 days ago
89%
Bullish Trend 3 days ago
74%
MACD
ODDS (%)
Bearish Trend 3 days ago
81%
Bullish Trend 3 days ago
85%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
88%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
84%
Bullish Trend 3 days ago
73%
Advances
ODDS (%)
N/A
Bullish Trend 4 days ago
70%
Declines
ODDS (%)
Bearish Trend 3 days ago
85%
N/A
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
86%
Bearish Trend 3 days ago
90%
Aroon
ODDS (%)
Bullish Trend 3 days ago
88%
Bullish Trend 3 days ago
81%
View a ticker or compare two or three
Interact to see
Advertisement
PGEN
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ARSSF0.64N/A
N/A
Assura Plc
KGTFY13.46N/A
N/A
Krung Thai Bank Public Co., Ltd.
ANSNF0.03N/A
N/A
Anson Resources
MMTRS28.45N/A
N/A
Mills Music Trust
ASVRX9.44-0.02
-0.21%
American Century Small Cap Value R

PGEN and

Correlation & Price change

A.I.dvisor indicates that over the last year, PGEN has been loosely correlated with ARCT. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if PGEN jumps, then ARCT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PGEN
1D Price
Change %
PGEN100%
-1.40%
ARCT - PGEN
47%
Loosely correlated
-7.49%
TRDA - PGEN
45%
Loosely correlated
-1.57%
ARWR - PGEN
45%
Loosely correlated
+0.06%
CRSP - PGEN
45%
Loosely correlated
N/A
XENE - PGEN
44%
Loosely correlated
+0.62%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with EYPT. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then EYPT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
-0.83%
EYPT - VNDA
41%
Loosely correlated
-7.04%
PGEN - VNDA
40%
Loosely correlated
-0.70%
AVIR - VNDA
39%
Loosely correlated
-2.27%
CLDX - VNDA
39%
Loosely correlated
-4.16%
AURA - VNDA
38%
Loosely correlated
-0.16%
More